Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK’s Focuses Bioelectronics Quest On Blocking Single-Organ Neural Signals

This article was originally published in The Pink Sheet Daily

Executive Summary

In the final part of its three-prong effort to advance the nascent field of bioelectronics, GSK will award a $1 million prize to researchers who are first able to solve the single-organ nerve interface challenge. Previously, the pharma launched its bioelectronics R&D unit and Action Potential Venture Capital to spur progress in this area.

You may also be interested in...



GSK Ventures Into The Device World Through Bioelectronic Investment

The British pharma has financed a new venture fund to create a presence in an emerging technology and help jump-start the fledgling industry because it believes that the science has reached a transition point.

GSK Makes New Adult Immunization Push, Seeks Reimbursement Changes Following RSV Approvals

From ACIP to Part D to data transparency, GSK has several policy asks as it prepares to launch its new RSV vaccine for older adults. The Pink Sheet spoke with GSK’s vaccine policy lead about the firm’s new data platform and the worrisome US vaccination trends following the Covid pandemic.

Medicare Registry Plan For Alzheimer’s Drugs Pairs CMS Web Portal With Health System Efforts

Lack of detail on data elements that would be required through the portal has stakeholders wondering if the Centers for Medicare and Medicaid Services has really found a way to make the registry requirement less of a threat to access for Alzheimer’s drugs with traditional FDA approval.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

PS075179

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel